93 results on '"Kauffmann-Guerrero, Diego"'
Search Results
2. Early mortality in German patients with lung cancer: risk factors associated with 30-and 60-day mortality
3. Guideline adherence of tumor board recommendations in lung cancer and transfer into clinical practice
4. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
5. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
6. Tumor seeding following CT- guided transthoracic needle biopsy in lung cancer. A case report
7. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
8. Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition
9. A new approach for the detection of obesity-related airway obstruction in lung-healthy individuals
10. The Role of Thoracic Surgery in Small Cell Lung Cancer – A Large Longitudinal Analysis (2002-2015) Based on Real-World Data
11. Consequences of the COVID-19 pandemic on lung cancer care and patient health in a German lung cancer center: results from a cross-sectional questionnaire
12. Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.
13. Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)
14. Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition
15. The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [ 18 F]FDG-PET/CT of Patients with Lung Cancer.
16. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
17. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
18. Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
19. Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab
20. Hyperinflation and reduced diffusing capacity predict prognosis in SCLC: value of extended pre-therapeutic lung function testing.
21. SCLC–State of the Art and What Does the Future Have in Store?
22. Clinical relevance of the M1b and M1c descriptors from the proposed TNM 8 classification of lung cancer
23. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients.
24. Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality.
25. Changes in Behavior After Vaccination and Opinions Toward Mask Wearing: Thoracic Oncology Patient–Reported Experiences During the COVID-19 Pandemic.
26. Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET.
27. Markers of Immune Cell Exhaustion as Predictor of Survival in Surgically-Treated Early-Stage NSCLC.
28. Lymphocytes and sinus histiocytosis in tumor and matched lymph nodes as predictors of survival in non-small-cell lung cancer.
29. Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs.
30. Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
31. Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies.
32. New developments in locally advanced nonsmall cell lungcancer.
33. Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences.
34. Deterioration and Mortality Risk of COPD Patients Not Fitting into Standard GOLD Categories: Results of the COSYCONET Cohort.
35. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
36. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
37. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
38. 68Ga-EMP-100 PET/CT—a novel method for non-invasive assessment of c-MET expression in non-small cell lung cancer.
39. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
40. Daily Routine and Access to Care: Initial Patient Reported Experiences at a German Lung Cancer Center during the COVID-19 Pandemic.
41. Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC.
42. Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography.
43. NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.
44. Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer.
45. Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer.
46. Klinische Relevanz der M1b- und M1c-Deskriptoren der neuen TNM-8-Klassifikation des Lungenkarzinoms.
47. Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment.
48. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort.
49. Dermal Filler Injections Mimic Tumor Activity during Immune Checkpoint Inhibition.
50. Black and Blue.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.